FDA Approved Indications for this Orphan Drug:

Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.

FDA Marketing Approval issued as of:
12/26/1990

Orphan Drug exclusivity ends on:
12/26/1997
Company Making and Marketing this drug:
Medimmune Oncology, Inc.

FDA Designation Date:
2/9/84

FDA Drug Designation:
Treatment of advanced adenocarcinoma of the ovary.